Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,081 to 4,100 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Gepotidacin vs Nitrofurantoin: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 285 of 804 200 of 798 | 10.4 points 5.9 to 14.8 | 1,602 | NCT04187144 Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI) |
| Gepotidacin vs Nitrofurantoin: Number of Participants With Serious Adverse Events (SAEs) | 5 of 804 5 of 798 | -0.0 points -0.9 to 0.9 | 1,602 | NCT04187144 Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI) |
| Gepotidacin vs Nitrofurantoin: serious adverse events | 5 of 804 5 of 798 | -0.0 points -0.9 to 0.9 | 1,602 | NCT04187144 Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI) |
| Acute Pain - Immediate PGx Testing vs Acute Pain - Delayed PGx Testing: deaths from any cause | 1 of 801 2 of 801 | -0.1 points -0.8 to 0.5 | 1,602 | NCT05966129 A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial) |
| 300 IR vs Placebo: serious adverse events | 21 of 800 9 of 801 | 1.5 points 0.2 to 3.0 | 1,601 | NCT02443805 Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR |
| Dabigatran 220mg vs Enoxaparin: Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period | 18 of 805 33 of 795 | -1.9 points -3.7 to -0.2 | 1,600 | NCT00657150 Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty |
| Regional Anesthesia vs General Anesthesia: Major Inpatient Morbidity | 98 of 795 120 of 805 | -2.6 points -5.9 to 0.8 | 1,600 | NCT02507505 Regional Versus General Anesthesia for Promoting Independence After Hip Fracture |
| Regional Anesthesia vs General Anesthesia: deaths from any cause | 98 of 795 92 of 805 | 0.9 points -2.3 to 4.1 | 1,600 | NCT02507505 Regional Versus General Anesthesia for Promoting Independence After Hip Fracture |
| Regional Anesthesia vs General Anesthesia: serious adverse events | 255 of 795 242 of 805 | 2.0 points -2.5 to 6.5 | 1,600 | NCT02507505 Regional Versus General Anesthesia for Promoting Independence After Hip Fracture |
| IDeg U200 vs IGlar U300: deaths from any cause | 7 of 802 9 of 798 | -0.3 points -1.4 to 0.8 | 1,600 | NCT03078478 A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs |
| IDeg U200 vs IGlar U300: serious adverse events | 167 of 802 141 of 798 | 3.2 points -0.7 to 7.0 | 1,600 | NCT03078478 A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs |
| Evolocumab in Parent Study vs Placebo in Parent Study: deaths from any cause | 51 of 855 35 of 745 | 1.3 points -1.0 to 3.5 | 1,600 | NCT03080935 Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries |
| Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: ISTH Major Bleeding | 38 of 797 30 of 803 | 1.0 points -1.0 to 3.1 | 1,600 | NCT03795298 Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation |
| Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: Primary Safety Endpoint: Non-procedural Bleeding | 137 of 797 65 of 803 | 9.1 points 5.9 to 12.3 | 1,600 | NCT03795298 Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation |
| Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: deaths from any cause | 35 of 797 31 of 803 | 0.5 points -1.5 to 2.5 | 1,600 | NCT03795298 Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation |
| Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: Primary Effectiveness Endpoint: Stroke, All Cause Death, and Systemic Embolism | 44 of 797 41 of 803 | 0.4 points -1.8 to 2.7 | 1,600 | NCT03795298 Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation |
| Oral Anticoagulant (Control) vs WATCHMAN FLX DEVICE: serious adverse events | 797 of 797 803 of 803 | 0.0 points -0.5 to 0.5 | 1,600 | NCT03795298 Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation |
| Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study vs Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study: Number of Participants Who Experienced an Adverse Event | 810 of 854 686 of 745 | 2.8 points 0.3 to 5.3 | 1,599 | NCT03080935 Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries |
| Evolocumab in Parent Study vs Placebo in Parent Study: serious adverse events | 410 of 854 323 of 745 | 4.7 points -0.2 to 9.5 | 1,599 | NCT03080935 Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries |
| Intervention - Nocturnal Coverage vs Control - Standard of Care: MICU Mortality | 154 of 820 139 of 778 | 0.9 points -2.9 to 4.7 | 1,598 | NCT01434823 24 Hour Intensivist Coverage in the Medical Intensive Care Unit |
Code
curl "https://conductscience.org/api/comparisons/v1?page=205"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=205
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04187144-6cb4949c",
"title": "Gepotidacin vs Nitrofurantoin: Number of Participants With Treatment-emergent Adverse Events (TEAEs)",
"summary": "285 of 804 against 200 of 798; risk difference 10.4 points, 95% interval 5.9 to 14.8; NCT04187144, Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)",
"record": "/library/comparisons/NCT04187144-6cb4949c",
"nct_id": "NCT04187144",
"kind": "outcome",
"participants": 1602,
"risk_difference": {
"value": 0.10385104552425845,
"lower": 0.05893160675830204,
"upper": 0.14818638007792148
},
"group_1": "285 of 804",
"group_2": "200 of 798",
"difference": "10.4 points",
"interval": "5.9 to 14.8",
"trial_title": "Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)"
},
{
"id": "NCT04187144-ca85f5ef",
"title": "Gepotidacin vs Nitrofurantoin: Number of Participants With Serious Adverse Events (SAEs)",
"summary": "5 of 804 against 5 of 798; risk difference -0.0 points, 95% interval -0.9 to 0.9; NCT04187144, Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)",
"record": "/library/comparisons/NCT04187144-ca85f5ef",
"nct_id": "NCT04187144",
"kind": "outcome",
"participants": 1602,
"risk_difference": {
"value": -0.00004675868776418592,
"lower": -0.00909373963353553,
"upper": 0.00895439764563561
},
"group_1": "5 of 804",
"group_2": "5 of 798",
"difference": "-0.0 points",
"interval": "-0.9 to 0.9",
"trial_title": "Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=206",
"request_id": "jO2Jz6apcYOZ_9iU"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant